At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
fondaparinux sodiumdrug
Likely dose
fondaparinux sodium 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial
Masonic Cancer Center, University of Minnesota·interventional·Posted Sep 28, 2006·Updated Dec 28, 2017
In Brief
A Phase 2 clinical trial evaluating fondaparinux sodium for Cervical Cancer and 7 related conditions. Completed, enrolled 44 participants across 2 sites.
Detailed Summary
RATIONALE: Fondaparinux may help prevent blood clots from forming in patients who are undergoing surgery for gynecologic cancer. PURPOSE: This phase II trial is studying how well fondaparinux works in preventing blood clots in patients undergoing surgery for gynecologic cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma, Thromboembolism, Vaginal Cancer, Vulvar Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2006
Enrollment StartJan 2007
Primary CompletionJan 2009
TodayJul 2026
First PostedSep 28, 2006
Enrollment StartJan 1, 2007
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 19.8 years ago
Interventions
fondaparinux sodiumdrug
Fondaparinux, 2.5 mg subcutaneous, Days 1-28 by mouth.